2,8-Dihydroxy-6H-dibenzo[c,h]chromene-12-carbonitrile | 550398-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: 2,8-Dihydroxy-6H-dibenzo[c,h]chromene-12-carbonitrile
• 英文别名: 2,8-dihydroxy-6H-naphtho[1,2-c]isochromene-12-carbonitrile
• CAS: 550398-69-1
• 化学式: C₁₈H₁₁NO₃
• 分子量: 289.29
• InChiKey: FVNQZVTUIUXBRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  73.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION
  申请人：CHANG Chien-Neng

  公开号：US20090010884A1

  公开（公告）日：2009-01-08

  The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

  本发明提供了使用一个或多个雌激素类药物预防、治疗或抑制皮肤炎症性疾病、紊乱或状况以及与胶原蛋白流失相关的疾病、紊乱或状况的组合物和方法。
• Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents
  申请人：Wyeth

  公开号：US20030176491A1

  公开（公告）日：2003-09-18

  This invention provides estrogen receptor modulators of formula I, having the structure 1 wherein R 1 , R 2 , R 3 , R 4 R 5 , R 6 , and R 7 are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这项发明提供了具有结构1的式I的雌激素受体调节剂，其中R1、R2、R3、R4、R5、R6和R7如规范中定义，或其药用盐。
• SUBSTITUTED 6H-DIBENZO[C,H]CHROMENES AS ESTROGENIC AGENTS
  申请人：Wyeth

  公开号：EP1453820B1

  公开（公告）日：2005-06-01
• USE OF ESTROGEN RECEPTOR BETA SELECTIVE LIGANDS FOR TREATING ACUTE LUNG INJURIES
  申请人：Wyeth

  公开号：EP2112926A2

  公开（公告）日：2009-11-04
• USE OF ER-BETA SELECTIVE LIGANDS FOR TREATING ACUTE LUNG INJURIES
  申请人：KEITH James C.

  公开号：US20080182872A1

  公开（公告）日：2008-07-31

  The present invention provides a method of treating acute lung injuries, such as acute lung injury induced by peritonitis during sepsis, acute lung injury induced by intravenous bacteremia during sepsis, acute lung injury caused by smoke inhalation, acute lung injury occurring in a premature infant with deficiency of surfactant, acute lung injury caused by oxygen toxicity or acute lung injury caused by barotraumas from mechanical ventilation, using an ERβ selective ligand such as 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol or 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile. The present invention further relates to use of ERβ selective ligands or compositions thereof for the prevention of acute lung injuries in those being at risk thereof.